EU approves Biogen's Spinraza for lead genetic cause of infant death

(Reuters) - Biogen Inc on Thursday said its drug, Spinraza, had secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news